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ABSTRACT
Background Chronic obstructive pulmonary disease
(COPD) is increasingly considered a heterogeneous
condition. It was hypothesised that COPD, as currently
defined, includes different clinically relevant subtypes.
Methods To identify and validate COPD subtypes, 342
subjects hospitalised for the first time because of
a COPD exacerbation were recruited. Three months after
discharge, when clinically stable, symptoms and quality
of life, lung function, exercise capacity, nutritional status,
biomarkers of systemic and bronchial inflammation,
sputum microbiology, CT of the thorax and
echocardiography were assessed. COPD groups were
identified by partitioning cluster analysis and validated
prospectively against cause-specific hospitalisations and
all-cause mortality during a 4 year follow-up.
Results Three COPD groups were identified: group 1
(n¼126, 67 years) was characterised by severe airflow
limitation (postbronchodilator forced expiratory volume in
1 s (FEV1) 38% predicted) and worse performance in
most of the respiratory domains of the disease; group 2
(n¼125, 69 years) showed milder airflow limitation (FEV1
63% predicted); and group 3 (n¼91, 67 years) combined
a similarly milder airflow limitation (FEV1 58% predicted)
with a high proportion of obesity, cardiovascular
disorders, diabetes and systemic inflammation. During
follow-up, group 1 had more frequent hospitalisations
due to COPD (HR 3.28, p<0.001) and higher all-cause
mortality (HR 2.36, p¼0.018) than the other two groups,
whereas group 3 had more admissions due to
cardiovascular disease (HR 2.87, p¼0.014).
Conclusions In patients with COPD recruited at their
first hospitalisation, three different COPD subtypes were
identified and prospectively validated: ‘severe respiratory
COPD’, ‘moderate respiratory COPD’, and ‘systemic
COPD’.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is
a heterogeneous disease with pulmonary and
extrapulmonary manifestations involving
a complex array of cellular, organic, functional and
clinical events.1e3 Understanding the phenotypic
heterogeneity of COPD and resolving it in well
deﬁned subgroups might result in improved prog-
nostic tools and better mechanistic studies,4e6 and
may prevent potentially useful treatments from
being discarded on the basis of trials that mixed up
various types of COPD.7
The interest in understanding COPD heteroge-
neity is not new. In the past, several COPD
subtypes were described based on clinical8 and
epidemiological9 observations. More recent studies
used factor analysis to identify independent factors
in COPD, such as exercise capacity and dyspnoea,
airﬂow limitation, hyperinﬂation, airway inﬂam-
mation or asthma features,10e16 or cluster analysis
to search for subgroups of COPD.17 18 These
studies, however, have important limitations. First,
most of them used a very limited range of variables
to describe COPD heterogeneity, and this carries
the risk of providing spurious results.6 Secondly,
only one of them18 included information on the
extrapulmonary manifestations of COPD,
a domain of the disease with a well established
clinical relevance today.2 3 Finally, and more
importantly, none of them assessed the predictive
validity of the new subtypes, so their clinical rele-
vance could not be shown.
To address all these limitations, the ‘Phenotype
and Course of COPD (PAC-COPD)’ study sought
to identify clinically and epidemiologically mean-
ingful COPD subtypes and to validate them by
assessing their relationship with clinically relevant
outcomes (hospitalisation and death) during
a 4 year follow-up.19 To this end, the PAC-COPD
study adopted a wide multidimensional approach
with a comprehensive clinical, functional, biolog-
ical and imaging characterisation of a well deﬁned
cohort of patients with COPD at the time of their
ﬁrst hospital admission because of an exacerbation
of the disease.20
METHODS
Design
The present study includes a cross-sectional anal-
ysis to identify COPD groups and a 4 year
prospective assessment of their relationship with
cause-speciﬁc admissions and all-cause mortality.
Subjects
We recruited all subjects hospitalised for the ﬁrst
time because of a COPD exacerbation in nine
teaching hospitals in Spain between January 2004
and March 2006. The diagnosis of COPD was
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conﬁrmed by spirometry when the patient had reached clinical
stability (see below), according to the criteria of the American
Thoracic Society (ATS) and the European Respiratory Society
(ERS) (postbronchodilator forced expiratory volume in 1 s
(FEV1) to forced vital capacity (FVC) ratio #0.7).3 The protocol
was approved by the Ethics Committees of all the participating
hospitals, and written informed consent was obtained from all
subjects. Detailed information about recruitment methods has
been previously published.21
Measurements
Detailed information about the methods, questionnaires,
standardisation of the tests and ﬁeldwork supervision is
provided in the Supplement material and has been previously
reported.19 Brieﬂy, 3 months after discharge, when clinically
stable, patients underwent a comprehensive characterisation
that required from two to four visits, on separate days, to the
participating hospitals, and included: (1) questionnaires covering
sociodemographic and environmental exposure data, smoking
habits, dietary habits, self-reported co-morbidities, previous
treatments and diagnoses, respiratory symptoms, health-related
quality of life, activities of daily living, sleepiness and psycho-
logical status; (2) detailed physical examination and Charlson
co-morbidity index obtained by a respiratory physician partici-
pating in the study; (3) body composition determination by
bioelectric impedance; (4) complete lung function tests including
forced spirometry, bronchodilator test, body plethysmography,
carbon monoxide diffusing capacity, resting arterial blood gases,
respiratory and peripheral muscle strength, and night-time pulse
oximetry; (5) 6-minute walk test (6MWT); (6) chest radio-
graphs; (7) skin prick tests; (8) induced sputum; (9) blood
laboratory analyses, including peripheral blood cell counts,
cholesterol, triglycerides and total immunoglobulin E (IgE); (10)
measurements of serum inﬂammatory and oxidative stress
markers, centralised in a single laboratory; and (11) Doppler
echocardiography evaluation. All these measurements were done
in the total sample of patients (n¼342). Additionally, due to
their technical and logistical requirements, the following
measurements could be performed only in some of the partici-
pating hospitals: (12) lung density and emphysema quantiﬁca-
tion from CT by a centralised evaluation using PulmoCT
(Siemens, Munich, Germany) (subsample 1: three hospitals, 102
subjects); (13) semiquantitative evaluation of bronchial wall
thickness on CT scans (subsample 2: four hospitals, 148
subjects); (14) microbiological culture of sputum (subsample 3: 8
hospitals, 224 subjects); (15) centralised measurement of
sputum inﬂammatory markers and differential cell counts
(subsample 4: 7 hospitals, 181 subjects); and (16) a cardiopul-
monary incremental exercise test (CPET) with cycloergometer
(subsample 5: 6 hospitals, 200 subjects). The overlap between
patients in subsamples is shown in Supplementary table 1.
COPD and cardiovascular admissions up to 31 December
2007 were obtained from national administrative databases.
Survival status until 31 December 2008 was obtained from
direct interview of the patients or their relatives.
Statistical analysis
A detailed version of the statistical analysis and power estima-
tion is available in the Supplement material.
From a total of 536 variables obtained, 224 were considered
after excluding those with additive relationships or resulting
from categorisations. Since missing values made up a small
proportion and were considered to be either completely random
or random,22 multiple imputation through chained equations23
was used to avoid losing data. Partitioning cluster analysis to
group subjects according to distribution of variables (stand-
ardised using Z-scores) was done by the k-means method,24 thus
sorting participants into groups in a way that maximises
differences between groups and minimises differences within
groups. Six cluster analyses were built, one for the total sample
and one for each of the ﬁve subsamples. Clusters in the
subsamples included the 150 variables of the total sample in
addition to the speciﬁc variables of each subsample. We
compared the proﬁle of the distribution of the 150 variables
common to cluster analyses in the total sample and in each
subsample across the three groups identiﬁed separately in each
of the six cluster analyses, and tested the individual agreement
in the assigned cluster group using Kappa statistics.
To display graphically the COPD groups identiﬁed by cluster
analysis, we used standardised values of all variables, keeping or
changing (multiplying by 1) their sign for all values ranging
from +1 (less impairment) to e1 (more impairment), and
plotted these values with a colour intensity scale spanning from
yellow to red, respectively. To present the relative relevance of
each variable to the separation into cluster groups, F values were
computed as the ratio of the variance of the group means
(between-group variance) over the overall variance of the vari-
able (higher values meaning higher relevance), and was obtained
by means of linear regression models using the variable under
study as the outcome and the cluster group as the exposure.
Sociodemographic characteristics, lifestyle factors and environ-
mental exposures were tested as potential determinants of
cluster groups.
To validate the clinical relevance of the groups identiﬁed by
cluster analysis, admissions and mortality during follow-up were
compared across groups using KaplaneMeier curves and log-
rank tests. The inﬂuence of COPD severity in the association
between cluster groups and longitudinal outcomes was assessed
including either ATS/ERS severity stages3 or the U-BODE
(updated body mass index, airﬂow obstruction, dyspnoea and
exercise capacity) index20 in multivariate models. As sensitivity
analyses, we repeated cluster analyses excluding subjects with
pneumonia as the concomitant cause for their ﬁrst COPD
hospitalisation, as well as restricting it to males. We also
implemented a previously published variable selection procedure
that allows dropping noisy, non-informative or redundant vari-
ables, thus keeping a smaller number of variables that were used
to reconduct the cluster analysis.25 Analyses were performed
with Stata release 10.0 (2008, StataCorp LP), and R 2.6.2 (2008,
R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Among 604 elegible patients with COPD, the PAC-COPD
cohort included a total of 342 (57%) participants. There were no
relevant differences between participants and non-participants.
Supplementary ﬁgure 1 shows details about exclusions and non-
participation. PAC-COPD subjects were mainly men (93%),
with a mean age of 68 years and a mean postbronchodilator
FEV1 during clinical stability of 52% predicted (table 1).
The number of cluster groups when using k-means needs to be
prespeciﬁed. Since we had no a priori information for a rational
choice, we looked at the results of two and three cluster groups.
Figure 1 presents the distribution of variables according to both
options. Classifying participants in three groups maximised the
differences for systemic inﬂammation, nutritional status,
cardiovascular disorders and lung density, while keeping
a similar contrast for the remaining dimensions. Classiﬁcation in
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four or more groups did not result in meaningful patterns or
statistical advantage. Thus, separation of the study subjects into
three different COPD groups, including 126 (37%), 125 (36%)
and 91 (27%) patients, was considered the most clinically
meaningful option.
Group 1 was characterised by a higher prevalence and severity
of respiratory symptoms, poorer quality of life, worse lung
function, lower exercise capacity, lower lung density and
thickened bronchial walls (table 2). Group 2 exhibited less
overall respiratory impairment than group 1 except for lung
density, which was similar in both groups. Group 3 showed
a respiratory proﬁle similar to group 2 but with a greater prev-
alence of overweight, systemic inﬂammation, cardiovascular
diseases and diabetes. The complete distribution of values for
the 224 variables is provided in Supplementary table 3. Sensi-
tivity analyses showed very similar results after excluding
patients with pneumonia as the concomitant cause of their ﬁrst
COPD hospitalisation, or after restricting the analysis to males.
The variable selection procedure identiﬁed that 10 variables
(dyspnoea (modiﬁed Medical Research Council scale), St
George’s Respiratory Questionnaire-Activity, prebronchodilator
and postbronchodilator FEV1 (% predicted), thoracic gas volume
(TGV; % predicted), inspiratory to total lung capacity (IC/TLC)
ratio, PaO2, peripheral blood neutrophil count, body weight and
body mass index (BMI)) could be used to obtain the same cluster
groups with a mean concordance of 81% (table 2).
No relevant differences in potential risk factors were observed
between the three COPD groups (table 3). Remarkably, all
groups were of similar age. Smoking status was very similar
among them, but smoking history showed that group 2 quit
smoking at a younger age (a mean of 3 years earlier), and that
group 3 smoked more pack years.
During follow-up, group 1 had more frequent hospitalisations
due to COPD, and the highest all-cause mortality, whereas
group 3 had more admissions due to cardiovascular disease
(ﬁgure 2). After adjusting for disease severity, the observed
differences in admissions were unchanged (risk of COPD
admission in group 1 compared with group 2: unadjusted
HR¼3.28, ATS/ERS stages adjusted HR¼2.89 and U-BODE
adjusted HR¼2.45; risk of cardiovascular admission in group 3
compared with group 2: unadjusted HR¼2.87, ATS/ERS stages
adjusted HR¼2.88 and U-BODE adjusted HR¼2.27). The
differences in mortality remained similar but lost statistical
signiﬁcance (risk of mortality in group 1 compared with group 2:
unadjusted HR¼2.36, ATS/ERS stages adjusted HR¼2.01 and
U-BODE adjusted HR¼1.41) (Supplementary table 3).
DISCUSSION
In this cohort of 342 patients recruited at the time of their ﬁrst
COPD admission three different groups of COPD patients were
identiﬁed. Because each group included a large proportion of
subjects, and the groups exhibited marked clinical differences,
and were associated with different longitudinal outcomes, we
propose that they are clinically relevant COPD subtypes.
Subtype 1 showed the worst status in most of the respiratory
domains of the disease and exercise capacity. Subtype 2 was
characterised by a milder respiratory status than subtype 1, and
subtype 3 also by a milder respiratory status but a higher
prevalence of obesity, cardiovascular disease and diabetes, and
higher levels of systemic inﬂammatory markers.
Previous literature has suggested that part of the phenotypic
heterogeneity in COPD is due to a divergent distribution of
bronchial airway (chronic bronchitis) and parenchymal disease
(emphysema).1 In our study this was observed only in subtype
2, with a substantial degree of emphysema in the absence of
increased wall thickness, both according to CT measures. We
also found that asthma-like variables did not contribute to
phenotypic heterogeneity, contrasting with other publications.9
Our results cannot be directly compared with the studies
applying factor analysis in COPD,10e17 since these studies
identiﬁed a relatively large number of independent disease
components from a reduced number of variables. Cluster anal-
ysis, instead, allows segregating subjects in different groups.27
Its recent use18 in patients with COPD identiﬁed four groups,
one of them including obesity and chronic heart failure, in
keeping with our subtype 3.
Most of the features of the so-called metabolic syndrome,
including obesity, higher levels of triglycerides, diabetes,
ischaemic heart disease, arterial hypertension and elevated
serum levels of C-reactive protein and ﬁbrinogen, were clustered
in subtype 3. Fabbri and Rabe28 proposed that a ‘chronic
systemic inﬂammatory syndrome’ may contribute to the co-
morbidities that frequently co-exist in patients with COPD. Our
results give preliminary support to this concept because, ﬁrst,
we found that subtype 3 was characterised by both elevated
Table 1 Characteristics of the study participants (n¼342) at their first chronic obstructive pulmonary
disease (COPD) admission and during clinical stability*
At first
admission
During clinical stability at least
3 months after the admission
Gender: female, n (%) 24 (7.0) e
Age (years), mean (SD) 67.5 (8.5) 67.9 (8.6)
Low (IV, V) socioeconomic status, n (%) 259 (81.7) e
Active workers, n (%) 61 (17.8) 54 (15.8)
Smoking status: current smoker, n (%) 145 (42.4) 109 (32.9)
Charlson index of co-morbidity (score 0e30), median (P25eP75) 2 (1e2) 2 (1e3)
Modified Medical Research Council dyspnoea scale (score 0e5),
median (P25eP75)
3 (2e4) 2 (2e3)
Postbronchodilator forced expiratory volume in 1 s (% predicted),
mean (SD)
49.2 (15.7)y 52.4 (16.2)
Arterial oxygen partial pressure (mm Hg), mean (SD) 64.8 (12.0)y 74.3 (10.6)
Any respiratory drug treatment, n (%) 193 (56.4) 288 (85.2)
*Subjects were recruited during their first hospital admission because of a COPD exacerbation. The assessment of phenotype
heterogeneity (through the several tests and questionnaires) was done when the patient had reached clinical stability and at least
3 months after discharge (see text for more details).
yMeasured at hospital discharge.
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markers of systemic inﬂammation and a high prevalence of co-
morbidities; of note, 17% of patients in subtype 3 had congestive
heart failure, a ﬁgure that contrasts markedly with that seen in
subtypes 1 (5%) and 2 (1%). Secondly, obesity might have
contributed to systemic inﬂammation in subtype 3, as previ-
ously suggested.29 Finally, consistently with the hypothesis of
the ‘chronic systemic inﬂammatory syndrome’,28 subtype 3 had
a higher risk of COPD and cardiovascular admissions than
subtype 2. In contrast, the fact that we did not identify signif-
icant differences among subtypes in bronchial inﬂammatory
markers and, nonetheless, subtype 3 showed more systemic
inﬂammation than the other two, does not support previous
claims that pulmonary inﬂammation could ‘spill-over ’ from the
lungs.30
Despite the fact that airﬂow limitation in subtype 3 was
moderate and similar to that seen in subtype 2, patients in the
former subtype showed more dyspnoea and poorer health-
related quality of life and exercise capacity (actually quite similar
to those seen in subtype 1 with much more severe airﬂow
limitation). This is in agreement with the currently accepted
apparent paradox that lung function and other clinical param-
eters are weakly correlated in COPD,31 32 and might be
explained by the combined cardiorespiratory morbidity in
subtype 3. As a consequence, it is possible that in clinical trials,
this subtype may respond poorly to interventions targeting
airﬂow limitation.7 Equally important is that, in clinical prac-
tice, these patients may beneﬁt from an integrated cardiorespi-
ratory assessment and therapeutic plan.
One salient feature of our study is the large differences in
airﬂow limitation seen across the three identiﬁed subtypes, since
all patients were hospitalised for the ﬁrst time due to a COPD
exacerbation and had similar age and smoking trajectories. The
Figure 1 Graphical description of chronic obstructive pulmonary disease (COPD) groups identified by the cluster analysis. Each coloured line
represents a variable, whose level of impairment ranges from e1 (more impairment, in red) to +1 (less impairment, in yellow). Values from 1 to +1
correspond to standardised Z-scores, where 0 corresponds to the mean of the total population included in each sample or subsample. Six cluster
analyses were built, and, given their high concordance, their results are displayed using the same group categories (see Supplementary table 3 for
complete data of all cluster results and their concordance). To make comparisons easier to interpret, we grouped variables under dimensions, as
previously published.26
Thorax 2011;66:430e437. doi:10.1136/thx.2010.154484 433
Chronic obstructive pulmonary disease
 group.bmj.com on April 26, 2011 - Published by thorax.bmj.comDownloaded from 
possibility that patients in subtype 1 might be poor perceivers of
dyspnoea, a hypothesis that has not been formally explored in
COPD but is well established in asthma,33 should not be
excluded. The fact that patients in subtype 2 require hospital-
isation despite much milder airﬂow limitation may be explained
by a remarkable degree of emphysemadaccording to CT
scandwhich could result in a different clinical presentation at
the emergency room, leading to an admission. This subtype
reported the lowest proportion of respiratory diagnosis and
treatment before recruitment (data not shown) and could
represent the largest window of opportunity for improving early
diagnosis and management of COPD.
Although smoking is the main risk factor for COPD,2 we
found no evidence that it may be an important source of COPD
heterogeneity, though the larger number of pack-years reported
by subtype 3 may have contributed to their higher prevalence of
cardiovascular and metabolic disease. Likewise, other exposures
to occupational or environmental factors were not signiﬁcantly
different among COPD phenotypes although, admittedly,
limited information was available. Finally, it is worth noting
that patients in subtype 1 were, on average, 4 cm shorter than
those in subtype 3. Since height is considered a marker of in
utero and childhood lung growth, we hypothesise that subjects
in subtype 1 might have had impaired lungs since early life and,
for the same amount of smoking, developed a more severe
respiratory status at the time of their ﬁrst hospital admission.
The latter observation is consistent with recent reports on the
early origin of COPD.34 As height was included in the cluster
analysis, its interpretation as a potential risk factor can be
argued.
Some potential limitations of our study also need discussion.
The proportion of women included in the study was low, so its
Table 2 Description* of the three chronic obstructive pulmonary disease (COPD) groups identified by cluster analysis
All subjects
n[342
Group 1
n[126
Group 2
n[125
Group 3
n[91 Fy
Cough day or night, % 49 62 38 44 8.19
Sputum day or night, % 53 63 46 51 4.05
Asthma (self-reported), % 9 11 8 9 0.22
Dyspnoea (modified Medical Research Council scale, 0e5), mean 2.6 3.2 1.9 2.8 33.53
St George Respiratory Questionnaire-Symptoms (0e100), mean 49 54 44 47 11.35
St George Respiratory Questionnaire-Activity (0e100), mean 47 61 32 49 60.01
St George Respiratory Questionnaire-Impacts (0e100), mean 27 36 17 26 42.62
Prebronchodilator forced expiratory volume in 1 s (FEV1) (% predicted), mean 49 35 58 55 139.74
Postbronchodilator FEV1 (% predicted), mean 52 38 63 58 148.99
Postbronchodilator FEV1 to forced vital capacity ratio, mean 0.53 0.44 0.57 0.61 101.49
FEV1 bronchodilation change (% of prebronchodilator FEV1), mean 9.0 9.9 9.1 7.6 1.04
Thoracic gas volume (% predicted), mean 137 161 129 114 52.98
Inspiratory capacity/total lung capacity ratio, mean 0.31 0.23 0.34 0.37 95.26
Carbon monoxide diffusing capacity (% predicted), mean 65 54 73 70 13.67
Arterial oxygen partial pressure (mm Hg), mean 74 70 81 72 47.39
Time with arterial oxygen saturation <90% when sleeping (%), mean 19 26 6 27 23.88
Minimum arterial oxygen saturation during 6-minute walk test (%), mean 89 86 92 90 33.13
C-reactive protein in serum (mg/dl), mean 0.86 0.99 0.36 1.37 8.46
Fibrinogen in serum (g/l), mean 4.13 4.23 3.77 4.50 11.40
Tumour necrosis factor in serum (pg/ml), mean 0.87 0.88 0.72 1.05 1.37
Interleukin 6 in serum (pg/ml), mean 1.45 1.52 1.12 1.81 5.88
Peripheral blood neutrophil count (n3109/l), mean 4.62 4.76 3.94 5.35 23.55
Skin prick test (number of positive allergens), mean 0.18 0.13 0.18 0.25 1.53
Body weight (kg), mean 76 69 74 90 87.04
Height (cm), mean 1.64 1.62 1.64 1.66 11.24
Body mass index (kg/m2), mean 28.2 26.0 27.2 32.4 78.30
Fat free mass index (kg/m2), mean 19.6 18.6 19.3 21.6 29.53
6-Minute walk total distance (m), mean 434 414 466 417 8.52
Myocardial infarction (doctor diagnosed), % 11 6 7 23 9.40
Congestive heart failure (doctor diagnosed), % 7 5 1 17 11.14
Left ventricle telediastolic diameter (mm), mean 50.5 49.6 50.1 52.3 5.34
Ejection fraction (%), mean 59.3 59.7 58.8 59.5 0.25
Tricuspid insufficiency, % 58 66 61 43 4.63
Diabetes (doctor diagnosed), % 19 16 14 32 6.11
Density less than 950 Hounsfield units in both lung infracarinal thin
sections (%)z, mean
14 24 16 6 34.03
Bronchial wall thickness extension in right inferior lobe (score 0e3)z, mean 1.9 2.7 1.5 1.1 47.26
Potentially pathogenic microorganism colonisationz, % 34 36 35 26 0.79
Interleukin 8 (3103) in sputum supernatant (pg/ml)z, mean 10.11 11.90 8.54 8.98 2.72
Neutrophil count in sputum (n3106/ml)z, mean 370 250 290 570 1.59
Maximal oxygen uptake at cardiopulmonary incremental exercise test peak
(% predicted)z, mean
62 53 69 68 19.93
*Non-standardised values of a selection of 40 out of 224 variables in figure 1, including those obtained with the variable selection procedure (bold text) and variables selected according to
clinical experts’ knowledge. Complete data are provided in Supplementary table 3.
yF values correspond to the ratio of the variance of the group means (between-group variance) over the overall variance of the variable (higher values meaning higher relevance of the variable
for separating cluster groups), and were obtained by means of linear regression models using each variable as the outcome, and the cluster group as the exposure (see Supplement for details).
zVariables obtained in a subsample of patients (see text for details).
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results should be extrapolated to females with caution. The
intensive characterisation of this study was not feasible outside
a hospital setting, so identiﬁcation and validation of COPD
subtypes in different COPD populations is needed. Because of
such intensive characterisation, we did not include patients with
severe co-morbidities, although we consider it unlikely that this
would have distorted the observed subtypes given that they
were of similar ages. Our study was restricted to patients who
Table 3 Differences in sociodemographic characteristics, lifestyle factors and environmental exposures across the three chronic obstructive
pulmonary disease (COPD) groups identified by cluster analysis
Group 1
n[126
Group 2
n[125
Group 3
n[91 p Value
Sociodemographic characteristics
Gender: female, n (%) 8 (6.4) 11 (8.8) 5 (5.5) 0.601
Age (years), mean (SD) 67.4 (8.8) 68.8 (8.1) 67.4 (9.0) 0.346
Low (IV, V) socioeconomic status, n (%) 94 (79.0) 97 (82.2) 68 (85.0) 0.552
Lifestyle factors
Smoking status:
Never, n (%) 0 (0) 2 (1.6) 0 (0) 0.418
Former, n (%) 77 (63.1) 84 (68.9) 59 (67.8)
Current, n (%) 45 (36.9) 36 (29.5) 28 (32.2)
Age at onset of smoking (years), mean(SD) 15.3 (4.4) 16.2 (4.8) 16.9 (6.9) 0.104
Age at quitting smoking (years), mean (SD) 60.7 (9.1) 57.0 (11.6) 60.3 (10.1) 0.068
Time since quitting smoking (years), median (P25eP75) 1 (0e11) 1 (0e15) 1 (0e10) 0.291
Pack-years smoking, mean (SD) 68.6 (39.4) 59.4 (36.8) 79.4 (39.8) 0.001
Smoking duration (years), mean (SD) 45.8 (10.0) 42.8 (13.5) 44.5 (11.4) 0.121
Smoking intensity (pack/day), mean (SD) 1.2 (0.9) 1.1 (0.9) 1.4 (1.0) 0.098
Usual physical activity (kcals/week), median (P25eP75) 4508 (2412e8640) 6270 (4060e8757) 6366 (2655e9900) 0.020
Glucid intake (%), median (P25eP75) 39.9 (34.9e44.4) 38.7 (34.6e43.1) 37.9 (31.9e42.6) 0.276
Protein intake (%), median (P25eP75) 19.7 (17.5e22.2) 19.1 (17.5e22.3) 19.8 (17.6e21.5) 0.878
Lipid intake (%), median (P25eP75) 36.0 (32.0e39.4) 34.1 (31.1e38.3) 34.1 (30.1e38.3) 0.141
Fruit intake (g/d), median (P25eP75) 223 (147e327) 269 (176e373) 238 (160e350) 0.093
Vegetable intake (g/d), median (P25eP75) 291 (218e398) 295 (219e369) 243 (196e345) 0.204
Environmental exposures
Childhood exposure to wood or charcoal smoke, n (%) 98 (77.8) 106 (84.8) 68 (74.7) 0.160
Occupational exposure to vapours, gases, dust and fums
No/low exposure, n (%) 51 (46.4) 34 (30.9) 25 (22.7) 0.060
Moderate exposure, n (%) 28 (28.0) 42 (42.0) 30 (30.0)
High exposure, n (%) 30 (30.9) 38 (39.2) 29 (29.9)
Distance to the nearest high traffic road:
0e50 m, n (%) 99 (38.1) 93 (35.8) 68 (26.2) 0.881
51e200 m, n (%) 19 (35.2) 21 (38.9) 14 (25.9)
>201 m, n (%) 6 (27.3) 9 (40.9) 7 (31.8)
Figure 2 Patterns of hospital
admissions and mortality during
follow-up, according to the three
chronic obstructive pulmonary disease
(COPD) groups identified by cluster
analysis.
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were hospitalised for COPD and thus our ﬁndings may be
considered to apply only to relatively severe COPD. On the
other hand, the selection of patients at their ﬁrst hospital
admission due to COPD should be seen as a strength that allows
for a more valid study of the phenotypic heterogeneity of
COPD.35 Finally, our cluster analysis was cross-sectional, and
assessing the temporal stability of the identiﬁed COPD subtypes
remains an important issue.
The most obvious clinical implication of our study is that the
ﬁrst COPD hospitalisation offers an opportunity for a wider
than usual characterisation of patients with COPD. Actually,
that the longitudinal association between subtype 1 and COPD
admissions remained after adjusting for the two currently used
criteria to assess COPD severity3 32 suggests that our subtype
classiﬁcation builds relevant prognostic information that is not
accounted for in these criteria. Importantly, only 10 variables
that are usually collected in clinical practice would be enough to
separate patients into the described cluster groups. Further
research aiming to develop an allocating algorithm is needed. Of
course, experimental studies will be needed to assess whether
therapeutic strategies tailored to these subtypes can modify the
natural history of the disease.
In conclusion, in patients with COPD recruited at their ﬁrst
hospitalisation, three different COPD subtypes have been iden-
tiﬁed and prospectively validated, which we propose to label as
‘severe respiratory COPD’, ‘moderate respiratory COPD’, and
‘systemic COPD’.
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